Cargando…
Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy
Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a severe prognosis, and with a long-standing need for more effective therapeutic approaches. However, treatment with immune checkpoint inhibitors is becoming an increasingly effective strategy for MPM patients. In this scenario, e...
Autores principales: | Lofiego, Maria Fortunata, Cannito, Sara, Fazio, Carolina, Piazzini, Francesca, Cutaia, Ornella, Solmonese, Laura, Marzani, Francesco, Chiarucci, Carla, Di Giacomo, Anna Maria, Calabrò, Luana, Coral, Sandra, Maio, Michele, Covre, Alessia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715476/ https://www.ncbi.nlm.nih.gov/pubmed/34968251 http://dx.doi.org/10.3390/epigenomes5040027 |
Ejemplares similares
-
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival
por: Chiarucci, Carla, et al.
Publicado: (2020) -
Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy
por: Fazio, Carolina, et al.
Publicado: (2018) -
Immunotherapy of brain metastases: breaking a “dogma”
por: Di Giacomo, Anna Maria, et al.
Publicado: (2019) -
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study
por: Calabrò, Luana, et al.
Publicado: (2021) -
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy
por: Anichini, Andrea, et al.
Publicado: (2022)